MetaVia Extends Phase 1 Study of Obesity Drug DA-1726 to 8 Weeks

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotech focused on cardiometabolic diseases, has announced the extension of the 48 mg cohort in its Phase 1 trial of DA-1726, a dual GLP-1/glucagon receptor agonist for obesity. The study duration has doubled from 4 weeks to 8 weeks, with a fifth weekly dose already administered to the first patient.

Why the Extension?

• Goal: To evaluate longer-term early efficacy and identify the non-titrated maximum tolerated dose.
• Objective: To gather deeper data on safety, tolerability, and efficacy markers (like body weight, BMI, waist circumference).
• Top-line data expected: Q4 2025.

“This extension represents a meaningful step forward... it may position DA-1726 more strongly against current GLP-1 therapies,”

• Hyung Heon Kim, CEO of MetaVia

DA-1726: A Next-Gen Obesity Therapy

DA-1726 is a dual oxyntomodulin analog agonist, activating both:

• GLP-1 receptors (GLP1R) – reduces appetite
• Glucagon receptors (GCGR) – increases energy expenditure

Unique Features:

• 3:1 balanced GLP1R:GCGR activation — may offer better tolerability than current GLP-1 drugs
• Once-weekly subcutaneous dosing
• Potential for superior weight loss and cardiometabolic safety

Previously Reported Results (32 mg dose):

• Weight loss:
  - Average: 4.3%
  - Max: 6.3% by Day 26
• Satiety: 83% of patients reported early satiety
• Waist reduction: Up to 3.9 inches by Day 33
• Safety: Mild, transient GI side effects
• Cardiovascular/glycemic profile: Favorable

Phase 1 Study Design Highlights

• Type: Randomized, double-blind, placebo-controlled
• Participants: Obese (BMI 30–45), otherwise healthy adults
• Cohort size: 9 subjects per dose group (6 DA-1726 : 3 placebo)
• Extension: 4 more weekly doses added (total 8 weeks treatment)

Endpoints:

• Primary: Safety and tolerability (AEs, SAEs, TEAEs, discontinuation)
• Secondary: Pharmacokinetics (PK), metabolite profiling
• Exploratory:
  - Weight loss
  - BMI and waist changes
  - Lipids, glucose metabolism
  - Cardiovascular metrics

About DA-1726

• Mechanism: Dual GLP1R/GCGR agonist
• Target indications:
  - Obesity
  - MASH (Metabolic Dysfunction-Associated Steatohepatitis)
• Preclinical advantage:
  - Outperformed semaglutide (Wegovy®) and cotadutide in mice
  - Comparable weight loss to tirzepatide (Zepbound®) while preserving lean body mass
  - Improved lipid-lowering over survodutide

About MetaVia

MetaVia is advancing two main candidates:

1. DA-1726
   - Obesity & MASH
   - Strong potential in weight loss, BMI reduction, metabolic improvements
2. DA-1241
   - GPR119 agonist for MASH
   - Promotes gut hormone release (GLP-1, GIP, PYY)
   - Reduces hepatic inflammation, steatosis, fibrosis
   - Shows glucose-lowering and liver-targeted effects in early studies

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!